Objective: The original WEB-RADR project was launched in September 2014. The three-year project sought to utilise the powers of social media and new technologies for pharmacovigilance purposes. The project arose in response to the ninth call for Innovative Medicines Initiative (IMI) projects ‘WEBAE – Leveraging Emerging Technology for Pharmacovigilance’.


  • Amgen
  • AstraZeneca
  • Bayer
  • European Medicines Agency
  • Epidemico
  • GSK
  • Janssen Pharmaceutica
  • MedDRA
  • MHRA
  • Novartis Pharma
  • Sanofi-Aventis Research & Development
  • SRDC
  • UCB
  • University College London
  • University Medical Centre Groningen
  • University of Liverpool
  • Uppsala Monitoring Centre


Work Packages: To learn more about the individual work packages please see the Work Packages sub-pages:

Work Package 1: Governance and policy

Work Package 2A: Social media

Work Package 2B: Analytics

Work Package 3A: Mobile reporting platform

Work Package 3B: User based evaluation

Work Package 4: Scientific impact evaluation


See our WEB-RADR poster 


WEB-RADR Governance:

The WEB-RADR project had three levels of governance; the individual Work Packages, the Steering Committee and the General Advisory Board. Individual Work Packages met on weekly or bi-weekly to review work progression. Updates from individual Work Packages were reported at monthly Steering Committee meetings by Work Package Leaders. The General Advisory Board met on a yearly basis throughout the project. In addition every organisation contributed to the consortium assembly, a forum for sharing updates on project progress and outputs.




The WEB-RADR project was supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU) under grant agreement n° 115632, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.